Approval of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong consolidated results for Q3 FY26, with revenue from operations rising ~46% year-on-year to ₹123.4 crore (from ₹84.4 crore), driven by demand for registered products in international markets. EBITDA grew 67% YoY to ₹30 crore, with margins expanding from 22.0% to 24.3% on better product mix and cost efficiency. Profit after tax surged ~87% YoY to ₹16.0 crore in Q3. For 9M FY26, revenue rose 36% to ₹346 crore and PAT jumped 66% to ₹42 crore, with EBITDA margins improving from 21.4% to 23.0%. The company recorded an exceptional item of ₹82.94 lakhs related to incremental gratuity liability from new Labour Codes. Auditor Vijay Mehra & Co. issued an unqualified limited review report. Management reiterated its ₹500 crore FY26 revenue target and guided for ₹650 crore in FY27.
This is a strong quarterly performance with double-digit revenue and profit growth alongside margin expansion, likely to be viewed positively by investors. The exceptional Labour Code charge is non-recurring and regulatory-driven, so it should not weigh on the underlying growth narrative. Continued capex funded through internal accruals signals healthy cash generation.